Scienture (SCNX) 10-K 27 Mar 23 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 23, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-39199
Entity Registrant Name	TRxADE HEALTH, INC.
Entity Central Index Key	0001382574
Entity Tax Identification Number	46-3673928
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2420 Brunello Trace.
Entity Address, City or Town	Lutz
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33558
City Area Code	(800)
Local Phone Number	261-0281
Title of 12(b) Security	Common Stock, $0.00001 Par Value Per Share
Trading Symbol	MEDS
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 16,921,890
Entity Common Stock, Shares Outstanding		10,110,878
Documents Incorporated by Reference	Portions of the registrant’s definitive proxy statement relating to its 2023 annual meeting of stockholders (the “2023 Proxy Statement”) are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2023 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.
ICFR Auditor Attestation Flag	false
Auditor Firm ID	206
Auditor Name	MaloneBailey, LLP
Auditor Location	Houston, Texas

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current Assets
Cash	$ 1,133,633	$ 3,122,578
Accounts receivable, net	728,964	978,973
Inventory	119,582	56,279
Prepaid assets	110,944	216,414
Total Current Assets	2,093,123	4,374,244
Property plant and equipment, net	65,214	98,751
Intangible assets and capitalized software, net	450,845
Deposits	49,029	60,136
Operating lease right-of-use assets	1,051,815	1,233,033
Total Assets	3,710,026	5,766,164
Current Liabilities
Accounts payable	729,153	477,028
Accrued liabilities	290,013	270,437
Other current liabilities	67,517
Contingent funding liabilities	108,036
Current portion lease liabilities	196,872	178,561
Warrant liability	588,533
Notes payable— related party	166,667
Total Current liabilities	2,146,791	926,026
Long Term Liabilities
Other long-term liabilities — leases	887,035	1,069,965
Notes payable- related party	333,333
Total Liabilities	3,367,159	1,995,991
Stockholders’ Equity
Series A preferred stock, $0.00001 par value; 10,000,000 shares authorized; none issued and outstanding as of December 31, 2022 and December 31, 2021
Common stock, $0.00001 par value; 100,000,000 shares authorized; 9,393,708, and 8,166,457 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively	99	82
Additional paid-in capital	20,482,573	20,017,528
Retained deficit	(19,719,536)	(16,247,437)
Total TRxADE Health, Inc stockholders’ equity	763,136	3,770,173
Non-controlling interest in subsidiary	(420,269)
Total stockholders’ equity	342,867	3,770,173
Total Liabilities and Stockholders’ Equity	$ 3,710,026	$ 5,766,164

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	9,393,708	8,166,457
Common stock, shares outstanding	9,393,708	8,166,457

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenues	$ 11,448,265	$ 9,889,433
Cost of Sales	5,997,049	5,143,468
Gross Profit	5,451,216	4,745,965
Operating Expenses:
Impairment of intangible asset	792,500
Loss on inventory investment	875,250	1,226,426
Loss on write-down of inventory		376,348
Wage and salary expense	3,941,475	3,846,522
Professional fees	519,642	1,094,917
Accounting and legal expense	830,355	697,825
Technology expense	1,160,856	899,705
General and administrative	1,755,433	1,896,515
Total operating expenses	9,875,511	10,038,258
Operating Loss	(4,424,295)	(5,292,293)
Other income (expense)
Change in fair value of warrant liability	825,544
Interest income	20,989
Gain on disposal of asset	4,100
Interest expense	(336,206)	(23,590)
Total nonoperating expense	514,427	(23,590)
Net Loss	(3,909,868)	(5,315,883)
Net loss attributable to TRxADE Health, Inc.	(3,472,099)	(5,315,883)
Net loss attributable to non-controlling interests	$ (437,769)
Net loss per common share — basic and diluted	$ (0.41)	$ (0.65)
Weighted average common shares outstanding - basic and diluted	8,472,946	8,136,740

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Dec. 31, 2020		$ 81	$ 19,610,631	$ (10,931,554)		$ 8,679,158
Beginning balance, shares at Dec. 31, 2020		8,093,199
Common stock issued for services			181,163			181,163
Common stock issued for services, shares		37,905
Warrants exercised for cash		$ 1	15,000			15,001
Warrants exercised for cash, shares		5,000
Warrants expense			21,640			21,640
Option exercised for cash			1,821			1,821
Options exercised for cash, shares		30,353
Options expense			187,273			187,273
Net loss				(5,315,883)		(5,315,883)
Ending balance, value at Dec. 31, 2021		$ 82	20,017,528	(16,247,437)		3,770,173
Ending balance, shares at Dec. 31, 2021		8,166,457
Common stock issued for services		$ 2	254,104			254,106
Common stock issued for services, shares		292,667
Warrants exercised for cash		$ 0	875			875
Warrants exercised for cash, shares		14,584
Options expense			79,163			79,163
Net loss				(3,472,099)	(437,769)	(3,909,868)
Capital Contributions					792,500	792,500
Capital Distribution					(775,000)	(775,000)
Common stock issued for placement, net issuance costs		$ 15	130,903			130,918
Common stock issued for placement, net issuance costs, shares		920,000
Ending balance, value at Dec. 31, 2022		$ 99	$ 20,482,573	$ (19,719,536)	$ (420,269)	$ 342,867
Ending balance, shares at Dec. 31, 2022		9,393,708

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (3,909,868)	$ (5,315,883)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	14,637	7,351
Options expense	79,163	187,273
Common stock issued for services	254,106	181,163
Bad debt expense	(246,683)	615,657
Warrant Expense		21,640
Loss on write-off of intangible asset	792,500
Loss on write-down of inventory	875,250	376,348
Loss on inventory investments		143,891
Gain on sale of asset	(4,100)
Amortization of right of use assets	181,218	131,558
Changes in operating assets and liabilities:
Accounts receivable, net	496,692	(789,587)
Prepaid assets and deposits	336,928	(103,666)
Inventory	(63,303)	825,127
Other receivables	(875,250)	1,087,675
Lease liability	(164,618)	(131,153)
Accounts payable	252,125	220,199
Accrued liabilities	(200,776)	(13,819)
Current liabilities	67,517
Warrant liability	588,533
Customer deposits		(10,000)
Net cash used in operating activities	(1,525,929)	(2,566,226)
Cash flows from investing activities:
Purchase of fixed assets		(22,596)
Sale of fixed assets	23,000
Investment in capitalized software	(450,845)
Net cash used in investing activities	(427,845)	(22,596)
Cash flows from financing activities:
Repayments of Promissory Notes - Related Parties		(225,000)
Repayment of contingent liability	(716,964)
Distributions to non-controlling interest	(275,000)
Proceeds from sale of future revenue	825,000
Proceeds from exercise of stock options		1,821
Proceeds from exercise of warrants	875	15,001
Proceeds from Issuance of Common Stock, net of issuance costs	130,918
Net cash provided by financing activities	(35,171)	(208,178)
Net decrease in cash	(1,988,945)	(2,797,000)
Cash at beginning of the year	3,122,578	5,919,578
Cash at end of the period	1,133,633	3,122,578
Supplemental disclosure of cash flow information
Cash paid for interest, net	336,206	28,337
Cash paid for income taxes
Non-Cash Transactions
Insurance premium financed	220,354
Note issued as SOSRx contribution	500,000
Intangible asset contribution from non-controlling interest	$ 792,500

ORGANIZATION

ORGANIZATION	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
ORGANIZATION	NOTE 1 – ORGANIZATION TRxADE HEALTH, INC. (“ we our Trxade Company 100 Trxade, Inc. operates a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories and services. Integra Pharma Solutions, LLC is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products. Community Specialty Pharmacy, LLC is an accredited independent retail pharmacy with a focus on specialty medications and a community-based model offering home delivery services to patients. Alliance Pharma Solutions, LLC (d.b.a. DelivMeds) has developed a same day Pharma delivery software – Delivmeds.com and invested in SyncHealth MSO, LLC a managed services organization in January 2019, which investment was divested in February 2020. Bonum Health, LLC, was formed to hold certain telehealth assets acquired in October 2019. The “ Bonum Health Hub 143,891 SOSRx, LLC was formed on February 15, 2022, the Company entered into a relationship with Exchange Health, LLC, a technology company providing an online platform for manufacturers and suppliers to sell and purchase pharmaceuticals (“Exchange Health”). SOSRx LLC, the created entity relating to the relationship, a Delaware limited liability company, was formed in February 2022, and is owned 51 49 MedCheks, LLC, was formed in January 2021 and is a patient-centered, digital, precision healthcare platform that lets patients consolidate and control their health data via a digital Health Passport. This product has been discontinued and MedCheks, LLC was subsequently dissolved in December 2021. On October 9, 2019, the Company’s Board of Directors, and on October 15, 2019, stockholders holding a majority of the Company’s outstanding voting shares, approved resolutions authorizing a reverse stock split of the outstanding shares of the Company’s common stock in the range from one-for-two (1-for-2) to one-for-ten (1-for-10) Stockholder Authority stock split ratio of 1-for-6 Reverse Stock Split Proportional adjustments were made to the conversion and exercise prices of the Company’s outstanding warrants and stock options, and to the number of shares issued and issuable under the Company’s stock incentive plans in connection with the Reverse Stock Split. The Reverse Stock Split did not affect any stockholder’s ownership percentage of the Company’s common stock, except to the limited extent that the Reverse Stock Split resulted in any stockholder owning a fractional share. Fractional shares of common stock were rounded up to the nearest whole share based on each holder’s aggregate ownership of the Company. All issued and outstanding shares of common stock, options and warrants to purchase common stock and per share amounts contained in the financial statements, have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“ GAAP The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of the Company’s management, who are responsible for their integrity and objectivity. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board, or the FASB, Accounting Standards Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. As of December 31, 2022 the Company had an accumulated deficit of $ 19.7 54,000 1.1 Liquidity – Historically, operations have been funded primarily through the sale of equity or debt securities and operating activities. In 2022, the Company raised approximately $ 1.5 million in capital (See Note 4 – Stockholders’ Equity). Use of Estimates Reclassification – Certain prior year amounts have been reclassified to conform to the current year presentation. The reclassification did not result in a change in the net loss. Principle of Consolidation Cash Accounts Receivable 246,683 615,657 247,861 Inventory no 0 376,348 Beneficial Conversion Features Fair Value of Financial Instruments Fair Value Measurements and Disclosures Level 1 Level 2 Level 3 The Company has warrant liabilities on its balance sheet at December 31, 2022 that are required to be measured and recorded at fair value on a recurring basis. The Company uses the Black Scholes method to calculate the liability. The carrying amounts of cash, accounts receivable, accounts payable, accrued liabilities and short-term debt approximate fair value because of the short-term nature of these instruments. The carrying amount of long-term debt approximates fair value because the debt is based on current rates at which the Company could borrow funds with similar maturities. Goodwill Intangibles Goodwill and Other no 792,000 15 44,100 792,000 Revenue Recognition Revenue from Contracts with Customers. Revenue Recognition Trxade, Inc. provides an online website service, a buying and selling marketplace for licensed Pharmaceutical Wholesalers to sell products and services to licensed Pharmacies. The Company charges Suppliers a transaction fee, a percentage of the purchase price of the Prescription Drugs and other products sold through its website service. The fulfillment of confirmed orders, including delivery and shipment of Prescription Drugs and other products, is the responsibility of the Supplier and not of the Company. The Company holds no inventory and assumes no responsibility for the shipment or delivery of any products or services from the Company’s website. The Company considers itself an agent for this revenue stream and as such, reports revenue as net. Step One: Identify the contract with the customer – Trxade, Inc.’s Terms and Use Agreement is acknowledged between the Wholesaler and Trxade, Inc. which outlines the terms and conditions. The collection is probable based on the credit evaluation of the Wholesaler. Step Two: Identify the performance obligations in the contract – The Company provides to the Supplier access to the online website, uploading of catalogs of products and Dashboard access to review status of inventory posted and processed orders. The Agreement requires the supplier to provide a catalog of pharmaceuticals for posting on the platform, deliver the pharmaceuticals and upon shipment remit the stated platform fee. Step Three: Determine the transaction price – The Fee Agreement outlines the fee based on the type of product, generic, brand or non-drug. There are no discounts for volume of transactions or early payment of invoices. Step Four: Allocate the transaction price – The Fee Agreement outlines the fee. There is no difference between contract price and “ stand-alone selling price Integra Pharma Solutions, LLC is a licensed wholesaler and sells to licensed pharmacies brand, generic and non-drug products. The Company takes orders for product and creates invoices for each order and recognizes revenue at the time the Customer receives the product. Customer returns are not material. Step One: Identify the contract with the customer – The Company requires that an application and a credit card for payment is completed by the Customer prior to the first order. Each transaction is evidenced by an order form sent by the customer and an invoice for the product is sent by the Company. The collection is probable based on the application and credit card information provided prior to the first order. Step Two: Identify the performance obligations in the contract – Each order is distinct and evidenced by the shipping order and invoice. Step Three: Determine the transaction price – The consideration is variable if product is returned. The variability is determined based on the return policy of the product manufacturer. There are no sales or volume discounts. The transaction price is determined at the time of the order evidenced by the invoice. Step Four: Allocate the transaction price – There is no difference between contract price and “ stand-alone selling price Community Specialty Pharmacy, LLC is in the retail pharmacy business. The Company fills prescriptions for drugs written by a doctor and recognizes revenue at the time the patient confirms delivery of the prescription. Customer returns are not material. Step One: Identify the contract with the customer – The prescription is written by a doctor for a customer and delivered to the Company. The prescription identifies the performance obligations in the contract. The Company fills the prescription and delivers to the Customer the prescription, fulfilling the contract. The collection is probable because there is confirmation that the customer has insurance for the reimbursement to the Company prior to filling of the prescription. Step Two: Identify the performance obligations in the contract – Each prescription is distinct to the Customer. Step Three: Determine the transaction price – The consideration is not variable. The transaction price is determined to be the price of the prescription at the time of delivery which considers the expected reimbursements from third party payors (e.g., pharmacy benefit managers, insurance companies and government agencies). Step Four: Allocate the transaction price – The price of the prescription invoiced represents the expected amount of reimbursement from third party payors. There is no difference between contract price and “ stand-alone selling price SOSRX LLC.: SOSRx provides pharmaceutical manufacturers with an efficient platform in which to divest short-dated, overstock, and slow-moving products to direct purchasers. SOSRx’s proprietary method researches the current market, allowing the manufacturer to list the optimal selling price for their products. Manufacturers list their short-dated overstock and slow-moving products by lot with pictures and descriptions. The manufacturer then determines which vetted and registered customers can bid on or outright purchase their products. Once products from a manufacturer have been entered into SOSRx’s platform, a bid cycle begins. Each bid cycle is 3 days. Each buyer (wholesaler, distributor or chain) will have 3 options. The options are buy now, bid, or pass. In the buy now option the manufacturer has an established price in which they would sell the product. The bid option allows the buyers to put in a price if they value the product and at the end of the bid cycle the manufacturer has several options. The manufacturer can accept the highest bidder if the buyer has met the minimum bid requirement, counter if the bid is below the minimum bid requirement or begin a negotiation to an agreed upon price or accepted bid, regardless of minimum bid requirement. The fourth option is to decline. If one of the four options described above, except decline, have been selected a committed offer is generated in the system. The buyer then submits a purchase order to the manufacturer. The manufacturer then processes the purchase order and sends the product directly to the buyer. This is when revenue is recognized as a transaction fee. At no point does SOSRx take possession of the inventory. SOSRx bills the manufacturer per committed offer at a fee percentage of total offer value. Cost of Sales Stock-Based Compensation Compensation-Stock Compensation Income Taxes Income Taxes 100 Warrant Liability 2,663,045 Income (loss) Per Share 2,689,969 295,623 The following table sets forth the computation of basic and diluted income (loss) per common share for the years ended December 31, 2022, and 2021: SCHEDULE OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE December 31, 2022 December 31, 2021 Numerator: Net loss $ (3,909,868 ) $ (5,315,883 ) Numerator for basic and diluted EPS - income available to common stockholders (3,472,099 ) $ (5,315,883 ) Denominator: Denominator for basic and diluted EPS – weighted average shares 8,472,946 8,136,740 Basic and diluted loss per common share $ (0.41 ) $ (0.65 ) Concentration of Credit Risks and Major Customers 518,419 During the years ended December 31, 2022, no sales to customers represented greater than 10 Recent Accounting Pronouncements Recently Issued Accounting Pronouncements Not Yet Adopted ASU 2016-13 The Company does not expect the adoption of this new accounting guidance to have a material impact on its financial position, results of operations, or cash flows.

SHORT-TERM DEBT AND RELATED PAR

SHORT-TERM DEBT AND RELATED PARTIES DEBT	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
SHORT-TERM DEBT AND RELATED PARTIES DEBT	NOTE 3 – SHORT-TERM DEBT AND RELATED PARTIES DEBT Related Party Promissory Notes In October 2018, in connection with the acquisition of Community Specialty Pharmacy, LLC, a $ 300,000 10 October 15, 2021 75,000 25,000 3.00 225,000 76,500 At December 31, 2022 and 2021, total related party debt was $ 0

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 4 – STOCKHOLDERS’ EQUITY In January of 2022, warrants to purchase 14,584 875 In August 2021, warrants to purchase 5,000 3.00 3.00 5,000 15,000 2022 Equity Compensation Awards On September 1, 2022, the Board of Directors and Compensation Committee, awarded shares to six employees and officers in lieu of reduced cash salary. In lieu of the reduced cash salary payable to each employee and Officer, the Board and Compensation Committee agreed to issue such officers and employees shares of the Company’s common stock equal to the amount of reduced cash salary set forth in the table above, divided by the closing sales price of the Company’s common stock on the NASDAQ Capital Market on August 31, 2022, the date approved by the Board of Directors. There was a total of 108,617 1.16 th 2022 Independent Director Compensation Effective on August 31, 2022, the Board of Directors approved the issuance of 54,525 63,250 th th All of the awards discussed above were issued under the Company’s Second Amended and Restated 2019 Plan and all restricted stock awards discussed above were evidenced by Restricted Stock Grant Agreements. There will be 1,407,276 2021 Equity Compensation Awards On April 15, 2021, the Board of Directors, with the recommendation of the Compensation Committee, approved the grant of options to purchase an aggregate of 17,500 th five years 4.76 In September of 2022 and effective on September 1, 2022 the Board of Directors with recommendation of the Compensation Committee, agreed to issue certain employees of the Company shares of the Company’s common stock in lieu of reductions to annual cash compensation. The employees agreed to reduce their salaries by an aggregate of $ 37,000 31,896 th In connection with and pursuant to the independent director compensation policy previously adopted by the Board of Directors, on April 15, 2021, the then three independent members of the Board of Directors (Mr. Donald G. Fell, Dr. Pamela Tenaerts, and Mr. Michael L. Peterson), were each awarded 10,721 55,000 5.13 th 165,000 68,750 16,082 The Board of Directors of the Company, on May 27, 2021, confirmed the vesting of 2,680 In connection with and pursuant to the independent director compensation policy previously adopted by the Board of Directors, on May 27, 2021, the Board of Directors awarded Charles L. Pope, and Christine L. Jennings, each independent members of the Board of Directors appointed to the Board of Directors on May 27, 2021, 10,912 41,250 3.78 64,167 Employment Agreement with Suren Ajjarapu, Chief Executive Officer In connection with our employment agreement with Mr. Suren Ajjarapu, our Chief Executive Officer, no stock or other equity compensation was granted for the year ended December 31, 2021. Effective September 1, 2022 the Board of Directors and Compensation Committee with the approval of the officers agreed to reduce the annual cash compensation of Mr. Suren Ajjarapu. The reduction was documented in a Second Amendment to Employment Agreement with Mr. Ajjarapu. Mr. Ajjarapu’ s annual compensation was reduced from $ 360,000 300,000 51,724 th Employment Agreement with Prashant Patel, Chief Operating Officer Effective September 1, 2022 the Board of Directors and Compensation Committee with the approval of the officers agreed to reduce the annual cash compensation of Mr. Prashant Patel. The reduction was documented in the First Amendment to Employment Agreement with Mr. Patel. Mr. Patel s annual compensation was reduced from $ 150,000 140,000 8,620 th Offer Letter with Ms. Huffman, Chief Financial Officer Effective September 1, 2022 the Board of Directors and Compensation Committee with the approval of the officers agreed to reduce the annual cash compensation of Ms. Huffman. The reduction was documented in an Amendment to Offer Letter with Ms. Huffman. Ms. Huffman’s annual compensation was reduced from $ 225,000 200,000 21,551 th On December 13, 2022 the Board of Directors with recommendation of the Compensation Committee approved the issuance of 50,000 Stock Repurchase Program On May 27, 2021, the Board of Directors of the Company authorized and approved a stock repurchase program for up to $ 1 There is no time frame for the repurchase program, and such program will remain in place until a maximum of $1.0 million of the Company’s common stock has been repurchased or until such program is suspended or discontinued by the Board of Directors. At the Market Offering On August 5, 2021, our Board of Directors paused the Stock Repurchase Program until the “at-the-market” offering (discussed below) was complete. On August 6, 2021, the Company entered into an Equity Distribution Agreement, relating to an “at-the-market” offering for the sale of up to $ 9 Effective on November 30, 2021, the Company provided the distribution agent notice of the termination of the Equity Distribution Agreement and the ATM Program (each of which were terminated effective December 5, 2021, pursuant to the terms of the Equity Distribution Agreement), and as a result, $ 128,000 No Continuation of the Stock Repurchase Program On December 10, 2021, the Board of Directors authorized and approved the resumption of the Company’s prior share repurchase program. The share repurchase program as approved by the Board of Directors on December 10, 2021, modified the prior repurchase program to allow for the repurchase of up to 100,000 There is no time frame for the repurchase program, and such program will remain in place until a maximum of 100,000 shares of the Company’s common stock has been repurchased or until such program is discontinued by the Board of Directors. As of December 31, 2022, no

PREFUNDED AND PRIVATE PLACEMENT

PREFUNDED AND PRIVATE PLACEMENT WARRANTS	12 Months Ended
	Dec. 31, 2022
Prefunded And Private Placement Warrants
PREFUNDED AND PRIVATE PLACEMENT WARRANTS	NOTE 5 – PREFUNDED AND PRIVATE PLACEMENT WARRANTS Simultaneously with the closing of the stock placement, the investor pre-purchased 601,740 1.14999 0.00001 1.50 0.232

WARRANTS

WARRANTS	12 Months Ended
	Dec. 31, 2022
Warrants
WARRANTS	NOTE 6 - WARRANTS In 2022, 2,663,045 14,584 3,027 In 2021, warrants to purchase 5,000 5,000 38,216 Note 4 – Stockholders’ Equity For the twelve-month period ended December 31, 2022 and 2021, warrants to purchase 14,584 5,000 875 15,000 The Company uses the Black-Scholes pricing model to estimate the fair value of stock-based awards on the date of the grant. There were 2,663,045 825,544 no The following table summarizes the assumptions used to estimate the fair value of the warrants granted during the years ended December 31, 2022 and 2021. SUMMARY OF ASSUMPTIONS USED TO ESTIMATE FAIR VALUE OF WARRANTS GRANTED 2022 2021 Expected dividend yield 0 % 0 % Weighted-average expected volatility 86 % 217 % Weighted-average risk-free interest rate 4.3 % 2.75 % Warrants, measurement input 4.3 % 2.75 % Expected life of warrants 5 5 The Company’s outstanding and exercisable warrants as of December 31, 2022 and 2021 are presented below: SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS Number Outstanding Weighted Average Exercise Price Contractual Life In Years Intrinsic Value Warrants outstanding as of December 31, 2020 82,751 $ 1.33 2.73 $ 352,951 Warrants granted 5,000 3.00 1.48 - Warrants forfeited, expired, cancelled (38,216 ) 2.51 - - Warrants exercised (5,000 ) 3.00 - - Warrants outstanding as of December 31, 2021 44,535 0.32 0.95 208,078 Warrants granted 2,663,045 1.50 4.77 - Warrants forfeited, expired, cancelled (3,027 ) 3.90 - - Warrants exercised (14,584 ) 0.06 - - Warrants outstanding as of December 31, 2022 2,689,969 1.50 4.72 6,731 Warrants exercisable as of December 31, 2022 2,689,969 1.50 4.72 6,731

OPTIONS

OPTIONS	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
OPTIONS	NOTE 7 - OPTIONS The Company maintains stock option plans under which certain employees are awarded option grants based on a combination of performance and tenure. The stock option plans provide for the grant of up to 2,333,333 2,000,000 st beginning in 2021 and ending in 2029 (each a “Date of Determination”), in each case subject to the approval and determination of the administrator of the plan (the Board of Directors or Compensation Committee) on or prior to the applicable Date of Determination, equal to the lesser of (A) ten percent (10%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares as determined by the administrator, provided that not more than 25 million shares of common stock may be issued pursuant to the exercise of incentive stock options pursuant to the plan. The administrator did not approve an increase in the number of shares covered under the plan as of April 1, 2021. For 2022, no 18,499 96,842 36,700 30,353 21,200 none four 4.86 5 For the twelve-month period ended December 31, 2021, options to purchase 30,353 1,821 Under the Black-Scholes option price model, fair value of the options granted in 2021 and 2020 were $ 168,008 557,308 The Company uses the Black-Scholes option pricing model to estimate the fair value of stock-based awards on the date of grant. There were no stock options granted during the year ended December 31, 2022. The following table summarizes the assumptions used to estimate the fair value of stock options granted during the year ended December 31, 2021: SCHEDULE OF ESTIMATE FAIR VALUE OF STOCK OPTIONS 2021 Expected dividend yield 0 % Weighted-average expected volatility 102 207 % Weighted-average risk-free interest rate 0.25 % Expected life of options 5 Total compensation cost related to stock options was $ 79,163 187,273 29,729 5 years SCHEDULE OF STOCK OPTION ACTIVITY Number Outstanding Weighted-Average Exercise Price Weighted-Average Contractual Life in Years Intrinsic Value Options outstanding as of December 31, 2020 425,817 $ 4.44 5.33 $ 597,332 Options exercisable as of December 31, 2020 282,167 4.52 4.56 384,226 Options granted 36,700 5.74 4.19 - Options forfeited (21,200 ) 6.45 4.11 - Options expired - - - - Options exercised (30,353 ) 0.06 - - Options outstanding as of December 31, 2021 410,964 $ 4.78 4.67 $ 368,417 Options exercisable as of December 31, 2021 302,191 4.88 4.38 257,186 Options granted - - - - Options forfeited (18,499 ) 5.82 4.91 - Options expired (96,842 ) 5.74 2.66 - Options exercised - - - - Options outstanding as of December 31, 2022 295,623 4.40 3.92 - Options exercisable as of December 31, 2022 257,506 4.42 3.89 -

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 8 – INCOME TAXES On December 22, 2017, H.R. 1, originally known as the Tax Cuts and Jobs Act, (the “ Tax Act Federal Tax Rate 35% 21% The statutory tax rate is the percentage imposed by law; the effective tax rate is the percentage of income actually paid by a company after considering tax deductions, exemptions, credits and operating loss carry forwards. At December 31, 2022 and 2021 deferred tax assets consist of the following: SCHEDULE OF DEFERRED TAX ASSETS December 31, 2022 December 31, 2021 Federal loss carryforwards $ 4,030,755 $ 2,347,266 Less: valuation allowance (4,030,755 ) (2,347,266 ) Deferred tax assets $ - $ - The Company has established a valuation allowance equal to the full amount of the deferred tax asset primarily due to uncertainty in the utilization of the net operating loss carry forwards. The estimated net operating loss carry forwards of approximately $ 17,105,445

OTHER RECEIVABLES

OTHER RECEIVABLES	12 Months Ended
	Dec. 31, 2022
Receivables [Abstract]
OTHER RECEIVABLES	NOTE 9 – OTHER RECEIVABLES On November 19, 2021, Integra filed a complaint against GSG PPE, LLC (“GSG”) and Gary Waxman (“Waxman”), the owner, alleging three counts of breach of contract for a purchase agreement, a promissory note, and a personal guaranty. Collectively, the company alleges that GSG and Waxman have materially breached all three contracts. In late 2020, GSG and Integra executed a valid initial contract setting the terms of a business transaction. GSG failed to pay Integra approximately 75% of the amount owed to Integra. GSG acknowledged it owed the money and executed a promissory note in favor of Integra in the amount of $ 630,000 630,000 630,000 630,000 743,000 248,000

CONTINGENCIES

CONTINGENCIES	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
CONTINGENCIES	CONTINGENCIES Studebaker Defense Group, LLC In July 2020, the Company’s wholly-owned subsidiary, Integra Pharma Solutions, LLC (“Integra”), entered into an agreement with Studebaker Defense Group, LLC (“Studebaker”) wherein Integra would pay Studebaker a down payment of $ 500,000 180,000 500,000 500,000 Sandwave Group Dsn Bhd and Crecom Burj Group SDN BHD In August 2020, Integra, entered into an agreement with Sandwave Group Dsn Bhd (“Sandwave”), wherein Integra would pay Sandwave a down payment of $ 581,250 150,000 581,250 581,250 581,250 Jain, et al., v. Memantine, et al. In January 2020, we became aware of a complaint filed by Jitendra Jain, Manish Arora, Scariy Kumaramangalam, Harsh Datta and Balvant Arora (collectively, plaintiffs), against our wholly-owned subsidiary, Trxade, Inc. and our Chief Executive Officer, Suren Ajjarapu as well as certain unrelated persons, Annapurna Gundlapalli, Gajan Mahendiran and Nexgen Memantine (collectively, defendants), in the Circuit Court of Madison County, Alabama (Case:47-CV-2019-902216.00). The complaint alleged causes of actions against the defendants including fraud in the inducement, relating to certain investments alleged to have been made by plaintiffs in Nexgen Memantine, breach of fiduciary duty, conversion and voidable transactions. The complaint related to certain investments alleged made by the plaintiffs in Nexgen Memantine and certain alleged fraudulent transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company.   On May 14, 2021, Plaintiffs filed a second amended complaint against the defendants. The second amended complaint alleges causes of action against the defendants including securities fraud, breach of fiduciary duty, violation of the Florida RICO Act, and breach of contract. The operative complaint relates to certain investments alleged to have been made by the plaintiffs in Nexgen Memantine and certain alleged transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company. The amended complaint seeks injunctive relief, $ 425,000   In February 2022, a settlement as to Suren Ajjarapu, Annapurna Gundlapalli and the Company was reached and signed. This settlement involved no admission of liability and a full and complete release of all actions after a lump-sum payment of $ 225,000

LEASES

LEASES	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
LEASES	NOTE 11 – LEASES The Company elected the practical expedient under ASU 2018-11 “ Leases: Targeted Improvements SCHEDULE OF OPERATING LEASES Lease 1 Lease 2 Initial Lease Term January 2021 to December 2021 November 2018 to November 2023 Renewal Lease Term - November 2023 to November 2028 New Initial Lease Term January 2022 to December 2026 - New Renewal Lease Term January 2027 to December 2031 - Initial Recognition of Right to use assets at January 1, 2019 $ 534,140 $ 313,301 New Initial Recognition of Right to use Assets at December 31, 2021 $ 977,220 $ - Incremental Borrowing Rate 10 % 10 % The Company entered into a new corporate office lease (Lease 1) on January 2022. The Company determined that entering into the new lease required remeasurement of the lease liability resulting in the increase of the right-of-use asset and the associated lease liability by $ 977,220 The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the operating lease liabilities recorded in the Consolidated Balance Sheet as of December 31, 2022. SCHEDULE OF FUTURE MINIMUM PAYMENTS FOR OPERATING LEASE LIABILITIES Amounts due within twelve months of December 31 2023 293,683 2024 302,494 2025 311,569 2026 320,916 Thereafter 105,531 Total minimum lease payments 1,334,193 Less: effect of discounting (264,228 ) Present value of future minimum lease payments 1,069,965 Less: current obligations under leases 195,475 Long-term lease obligations $ 874,490 The difference to the balance sheet above is due to the current and long-term remaining obligations of the copier lease not included in the amount of $ 13,943 For the years ended December 31, 2022, and 2021, amortization of right-of-use assets was $ 181,218 131,558 For the years ended December 31, 2022, and 2021, operating lease liabilities paid was $ 164,618 131,153

SEGMENT REPORTING

SEGMENT REPORTING	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE 12 – SEGMENT REPORTING The Company classifies its business interests into reportable segments which are Trxade, Inc., Community Specialty Pharmacy, LLC, Integra Pharma, LLC and Other (Unallocated). Operating segments are defined as the components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth opportunities of each respective segment. SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS Year Ended December 31, 2022 Trxade, Inc. CSP Integra Unallocated Total Revenue $ 5,435,814 $ 1,175,474 $ 4,754,067 $ 82,910 $ 11,448,265 Gross Profit 5,433,641 (90,678 ) 25,343 82,910 5,451,216 Segment Assets 1,877,881 (621,686 ) 445,264 2,008,567 3,710,026 Segment Profit/Loss 1,924,355 (469,778 ) (545,557 ) (4,818,888 ) (3,909,868 ) Cost of Sales $ 2,173 $ 1,266,152 $ 4,728,724 $ - $ 5,997,049 Year Ended December 31, 2021 Trxade, Inc. CSP Integra Unallocated Total Revenue $ 4,924,015 $ 1,652,841 $ 3,250,561 $ 62,016 $ 9,889,433 Gross Profit 4,921,084 156,785 (393,582 ) 61,678 4,745,965 Segment Assets 2,273,330 (431,593 ) 565,619 3,358,808 5,766,164 Segment Profit/Loss 1,977,938 (128,563 ) (2,749,028 ) (4,416,230 ) (5,315,883 ) Cost of Sales $ 2,931 $ 1,496,056 $ 3,644,143 $ 338 $ 5,143,468

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13 – SUBSEQUENT EVENTS Subsequent to December 31, 2022 and prior to the filing of this Form 10-K the Company had the following events. On January 3, 2023, Charles L. Pope resigned as a member of the Board of Directors. Until Mr. Pope’s resignation he also served as the Chairman of the Company’s Audit Committee and served on the Company’s Compensation Committee and Nominating and Governance Committee. On January 4, 2023, to fill the vacancy left by Mr. Pope’s resignation, the Board of Directors of the Company, with the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors, appointed Mr. Michael L. Peterson as a member of the Board of Directors. Mr. Peterson was also appointed to serve as the Chairperson of the Board of Director’s Audit Committee and as a member of the Compensation Committee and Nominating and Corporate Governance Committee. As part of Mr. Peterson’s compensation he will receive cash compensation in the amount of $ 55,000 20,000 th 100,000 55,000 On January 6, 2023, a restricted stock grant to Jeff Newell of 79,062 On January 6, 2023, the investor exercised their prefunded warrants in the amount of 601,740 6.02 .00001 On January 20, 2023, the Company entered into Membership Interest Purchase Agreements to sell 100% 125,000 100,000 266,000 On January 30, 2023, the Company received a delist determination letter from The Nasdaq Stock Market LLC. (the “Staff”), advising the Company that the Staff had determined that the Company was not in compliance with the minimum continued listing requirements of stockholders’ equity, and that the Company had not met the terms of the extension granted to them in in October 2022 to regain compliance by the deadline of January 25, 2023. Specifically, the Company did not complete its proposed transactions and was unable to file a Current Report Form 8-K by the January 25, 2023 deadline previously required by the Staff, evidencing compliance with the Rule. On February 6, 2023, the Company submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”), which request will stay any delisting action by the Staff at least until the hearing process concludes and any extension granted by the Panel expires. At the Panel hearing, the Company intends to present a plan to regain compliance with the minimum stockholders’ equity requirement. In the interim, the Company’s common stock will continue to trade on Nasdaq under the symbol “MEDS” at least pending the ultimate conclusion of the hearing process. Effective February 27, 2023, Ms. Janet Huffman, the Company’s Chief Financial Officer notified the Company of the termination of her Offer Letter dated February 3, 2022. Effective March 1, 2023, Ms. Huffman also transitioned from Chief Financial Officer to a consulting relationship with the Company instead of a full-time employee relationship. It is expected that Ms. Huffman will provide a set number of hours of her time to the Company and that the Company will engage a new Chief Financial Officer (or similar position) to replace Ms. Huffman. Effective March 6, 2023, Prashant Patel, a member of the Board of Directors, the President and the Chief Operating Officer of the Company, was appointed as Interim Principal Financial/Accounting Officer of the Company. On March 1, 2023, the Company issued 50,000 shares to White Lion Capital LLC as part of an agreement. On March 2, 2023, the Company entered into an agreement with Agile Capital Funding LLC., for an accounts receivable funding agreement in the amount of $ 787,500

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Going Concern	Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board, or the FASB, Accounting Standards Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. As of December 31, 2022 the Company had an accumulated deficit of $ 19.7 54,000 1.1
Liquidity	Liquidity – Historically, operations have been funded primarily through the sale of equity or debt securities and operating activities. In 2022, the Company raised approximately $ 1.5 million in capital (See Note 4 – Stockholders’ Equity).
Use of Estimates	Use of Estimates
Reclassification	Reclassification – Certain prior year amounts have been reclassified to conform to the current year presentation. The reclassification did not result in a change in the net loss.
Principle of Consolidation	Principle of Consolidation
Cash	Cash
Accounts Receivable	Accounts Receivable 246,683 615,657 247,861
Inventory	Inventory no 0 376,348
Beneficial Conversion Features	Beneficial Conversion Features
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair Value Measurements and Disclosures Level 1 Level 2 Level 3 The Company has warrant liabilities on its balance sheet at December 31, 2022 that are required to be measured and recorded at fair value on a recurring basis. The Company uses the Black Scholes method to calculate the liability. The carrying amounts of cash, accounts receivable, accounts payable, accrued liabilities and short-term debt approximate fair value because of the short-term nature of these instruments. The carrying amount of long-term debt approximates fair value because the debt is based on current rates at which the Company could borrow funds with similar maturities.
Goodwill	Goodwill Intangibles Goodwill and Other no 792,000 15 44,100 792,000
Revenue Recognition	Revenue Recognition Revenue from Contracts with Customers. Revenue Recognition Trxade, Inc. provides an online website service, a buying and selling marketplace for licensed Pharmaceutical Wholesalers to sell products and services to licensed Pharmacies. The Company charges Suppliers a transaction fee, a percentage of the purchase price of the Prescription Drugs and other products sold through its website service. The fulfillment of confirmed orders, including delivery and shipment of Prescription Drugs and other products, is the responsibility of the Supplier and not of the Company. The Company holds no inventory and assumes no responsibility for the shipment or delivery of any products or services from the Company’s website. The Company considers itself an agent for this revenue stream and as such, reports revenue as net. Step One: Identify the contract with the customer – Trxade, Inc.’s Terms and Use Agreement is acknowledged between the Wholesaler and Trxade, Inc. which outlines the terms and conditions. The collection is probable based on the credit evaluation of the Wholesaler. Step Two: Identify the performance obligations in the contract – The Company provides to the Supplier access to the online website, uploading of catalogs of products and Dashboard access to review status of inventory posted and processed orders. The Agreement requires the supplier to provide a catalog of pharmaceuticals for posting on the platform, deliver the pharmaceuticals and upon shipment remit the stated platform fee. Step Three: Determine the transaction price – The Fee Agreement outlines the fee based on the type of product, generic, brand or non-drug. There are no discounts for volume of transactions or early payment of invoices. Step Four: Allocate the transaction price – The Fee Agreement outlines the fee. There is no difference between contract price and “ stand-alone selling price Integra Pharma Solutions, LLC is a licensed wholesaler and sells to licensed pharmacies brand, generic and non-drug products. The Company takes orders for product and creates invoices for each order and recognizes revenue at the time the Customer receives the product. Customer returns are not material. Step One: Identify the contract with the customer – The Company requires that an application and a credit card for payment is completed by the Customer prior to the first order. Each transaction is evidenced by an order form sent by the customer and an invoice for the product is sent by the Company. The collection is probable based on the application and credit card information provided prior to the first order. Step Two: Identify the performance obligations in the contract – Each order is distinct and evidenced by the shipping order and invoice. Step Three: Determine the transaction price – The consideration is variable if product is returned. The variability is determined based on the return policy of the product manufacturer. There are no sales or volume discounts. The transaction price is determined at the time of the order evidenced by the invoice. Step Four: Allocate the transaction price – There is no difference between contract price and “ stand-alone selling price Community Specialty Pharmacy, LLC is in the retail pharmacy business. The Company fills prescriptions for drugs written by a doctor and recognizes revenue at the time the patient confirms delivery of the prescription. Customer returns are not material. Step One: Identify the contract with the customer – The prescription is written by a doctor for a customer and delivered to the Company. The prescription identifies the performance obligations in the contract. The Company fills the prescription and delivers to the Customer the prescription, fulfilling the contract. The collection is probable because there is confirmation that the customer has insurance for the reimbursement to the Company prior to filling of the prescription. Step Two: Identify the performance obligations in the contract – Each prescription is distinct to the Customer. Step Three: Determine the transaction price – The consideration is not variable. The transaction price is determined to be the price of the prescription at the time of delivery which considers the expected reimbursements from third party payors (e.g., pharmacy benefit managers, insurance companies and government agencies). Step Four: Allocate the transaction price – The price of the prescription invoiced represents the expected amount of reimbursement from third party payors. There is no difference between contract price and “ stand-alone selling price SOSRX LLC.: SOSRx provides pharmaceutical manufacturers with an efficient platform in which to divest short-dated, overstock, and slow-moving products to direct purchasers. SOSRx’s proprietary method researches the current market, allowing the manufacturer to list the optimal selling price for their products. Manufacturers list their short-dated overstock and slow-moving products by lot with pictures and descriptions. The manufacturer then determines which vetted and registered customers can bid on or outright purchase their products. Once products from a manufacturer have been entered into SOSRx’s platform, a bid cycle begins. Each bid cycle is 3 days. Each buyer (wholesaler, distributor or chain) will have 3 options. The options are buy now, bid, or pass. In the buy now option the manufacturer has an established price in which they would sell the product. The bid option allows the buyers to put in a price if they value the product and at the end of the bid cycle the manufacturer has several options. The manufacturer can accept the highest bidder if the buyer has met the minimum bid requirement, counter if the bid is below the minimum bid requirement or begin a negotiation to an agreed upon price or accepted bid, regardless of minimum bid requirement. The fourth option is to decline. If one of the four options described above, except decline, have been selected a committed offer is generated in the system. The buyer then submits a purchase order to the manufacturer. The manufacturer then processes the purchase order and sends the product directly to the buyer. This is when revenue is recognized as a transaction fee. At no point does SOSRx take possession of the inventory. SOSRx bills the manufacturer per committed offer at a fee percentage of total offer value.
Cost of Sales	Cost of Sales
Stock-Based Compensation	Stock-Based Compensation Compensation-Stock Compensation
Income Taxes	Income Taxes Income Taxes 100
Warrant Liability	Warrant Liability 2,663,045
Income (loss) Per Share	Income (loss) Per Share 2,689,969 295,623 The following table sets forth the computation of basic and diluted income (loss) per common share for the years ended December 31, 2022, and 2021: SCHEDULE OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE December 31, 2022 December 31, 2021 Numerator: Net loss $ (3,909,868 ) $ (5,315,883 ) Numerator for basic and diluted EPS - income available to common stockholders (3,472,099 ) $ (5,315,883 ) Denominator: Denominator for basic and diluted EPS – weighted average shares 8,472,946 8,136,740 Basic and diluted loss per common share $ (0.41 ) $ (0.65 )
Concentration of Credit Risks and Major Customers	Concentration of Credit Risks and Major Customers 518,419 During the years ended December 31, 2022, no sales to customers represented greater than 10
Recent Accounting Pronouncements	Recent Accounting Pronouncements
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted ASU 2016-13 The Company does not expect the adoption of this new accounting guidance to have a material impact on its financial position, results of operations, or cash flows.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
SCHEDULE OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE	The following table sets forth the computation of basic and diluted income (loss) per common share for the years ended December 31, 2022, and 2021: SCHEDULE OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE December 31, 2022 December 31, 2021 Numerator: Net loss $ (3,909,868 ) $ (5,315,883 ) Numerator for basic and diluted EPS - income available to common stockholders (3,472,099 ) $ (5,315,883 ) Denominator: Denominator for basic and diluted EPS – weighted average shares 8,472,946 8,136,740 Basic and diluted loss per common share $ (0.41 ) $ (0.65 )

WARRANTS (Tables)

WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2022
Warrants
SUMMARY OF ASSUMPTIONS USED TO ESTIMATE FAIR VALUE OF WARRANTS GRANTED	The following table summarizes the assumptions used to estimate the fair value of the warrants granted during the years ended December 31, 2022 and 2021. SUMMARY OF ASSUMPTIONS USED TO ESTIMATE FAIR VALUE OF WARRANTS GRANTED 2022 2021 Expected dividend yield 0 % 0 % Weighted-average expected volatility 86 % 217 % Weighted-average risk-free interest rate 4.3 % 2.75 % Warrants, measurement input 4.3 % 2.75 % Expected life of warrants 5 5
SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS	The Company’s outstanding and exercisable warrants as of December 31, 2022 and 2021 are presented below: SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS Number Outstanding Weighted Average Exercise Price Contractual Life In Years Intrinsic Value Warrants outstanding as of December 31, 2020 82,751 $ 1.33 2.73 $ 352,951 Warrants granted 5,000 3.00 1.48 - Warrants forfeited, expired, cancelled (38,216 ) 2.51 - - Warrants exercised (5,000 ) 3.00 - - Warrants outstanding as of December 31, 2021 44,535 0.32 0.95 208,078 Warrants granted 2,663,045 1.50 4.77 - Warrants forfeited, expired, cancelled (3,027 ) 3.90 - - Warrants exercised (14,584 ) 0.06 - - Warrants outstanding as of December 31, 2022 2,689,969 1.50 4.72 6,731 Warrants exercisable as of December 31, 2022 2,689,969 1.50 4.72 6,731

OPTIONS (Tables)

OPTIONS (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
SCHEDULE OF ESTIMATE FAIR VALUE OF STOCK OPTIONS	The Company uses the Black-Scholes option pricing model to estimate the fair value of stock-based awards on the date of grant. There were no stock options granted during the year ended December 31, 2022. The following table summarizes the assumptions used to estimate the fair value of stock options granted during the year ended December 31, 2021: SCHEDULE OF ESTIMATE FAIR VALUE OF STOCK OPTIONS 2021 Expected dividend yield 0 % Weighted-average expected volatility 102 207 % Weighted-average risk-free interest rate 0.25 % Expected life of options 5
SCHEDULE OF STOCK OPTION ACTIVITY	SCHEDULE OF STOCK OPTION ACTIVITY Number Outstanding Weighted-Average Exercise Price Weighted-Average Contractual Life in Years Intrinsic Value Options outstanding as of December 31, 2020 425,817 $ 4.44 5.33 $ 597,332 Options exercisable as of December 31, 2020 282,167 4.52 4.56 384,226 Options granted 36,700 5.74 4.19 - Options forfeited (21,200 ) 6.45 4.11 - Options expired - - - - Options exercised (30,353 ) 0.06 - - Options outstanding as of December 31, 2021 410,964 $ 4.78 4.67 $ 368,417 Options exercisable as of December 31, 2021 302,191 4.88 4.38 257,186 Options granted - - - - Options forfeited (18,499 ) 5.82 4.91 - Options expired (96,842 ) 5.74 2.66 - Options exercised - - - - Options outstanding as of December 31, 2022 295,623 4.40 3.92 - Options exercisable as of December 31, 2022 257,506 4.42 3.89 -

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
SCHEDULE OF DEFERRED TAX ASSETS	At December 31, 2022 and 2021 deferred tax assets consist of the following: SCHEDULE OF DEFERRED TAX ASSETS December 31, 2022 December 31, 2021 Federal loss carryforwards $ 4,030,755 $ 2,347,266 Less: valuation allowance (4,030,755 ) (2,347,266 ) Deferred tax assets $ - $ -

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
SCHEDULE OF OPERATING LEASES	SCHEDULE OF OPERATING LEASES Lease 1 Lease 2 Initial Lease Term January 2021 to December 2021 November 2018 to November 2023 Renewal Lease Term - November 2023 to November 2028 New Initial Lease Term January 2022 to December 2026 - New Renewal Lease Term January 2027 to December 2031 - Initial Recognition of Right to use assets at January 1, 2019 $ 534,140 $ 313,301 New Initial Recognition of Right to use Assets at December 31, 2021 $ 977,220 $ - Incremental Borrowing Rate 10 % 10 %
SCHEDULE OF FUTURE MINIMUM PAYMENTS FOR OPERATING LEASE LIABILITIES	SCHEDULE OF FUTURE MINIMUM PAYMENTS FOR OPERATING LEASE LIABILITIES Amounts due within twelve months of December 31 2023 293,683 2024 302,494 2025 311,569 2026 320,916 Thereafter 105,531 Total minimum lease payments 1,334,193 Less: effect of discounting (264,228 ) Present value of future minimum lease payments 1,069,965 Less: current obligations under leases 195,475 Long-term lease obligations $ 874,490

SEGMENT REPORTING (Tables)

SEGMENT REPORTING (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS	SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS Year Ended December 31, 2022 Trxade, Inc. CSP Integra Unallocated Total Revenue $ 5,435,814 $ 1,175,474 $ 4,754,067 $ 82,910 $ 11,448,265 Gross Profit 5,433,641 (90,678 ) 25,343 82,910 5,451,216 Segment Assets 1,877,881 (621,686 ) 445,264 2,008,567 3,710,026 Segment Profit/Loss 1,924,355 (469,778 ) (545,557 ) (4,818,888 ) (3,909,868 ) Cost of Sales $ 2,173 $ 1,266,152 $ 4,728,724 $ - $ 5,997,049 Year Ended December 31, 2021 Trxade, Inc. CSP Integra Unallocated Total Revenue $ 4,924,015 $ 1,652,841 $ 3,250,561 $ 62,016 $ 9,889,433 Gross Profit 4,921,084 156,785 (393,582 ) 61,678 4,745,965 Segment Assets 2,273,330 (431,593 ) 565,619 3,358,808 5,766,164 Segment Profit/Loss 1,977,938 (128,563 ) (2,749,028 ) (4,416,230 ) (5,315,883 ) Cost of Sales $ 2,931 $ 1,496,056 $ 3,644,143 $ 338 $ 5,143,468

ORGANIZATION (Details Narrative

ORGANIZATION (Details Narrative) - USD ($)			12 Months Ended
	Feb. 12, 2020	Oct. 09, 2019	Dec. 31, 2021	Dec. 31, 2022	Feb. 15, 2022
Reverse stock split, description	stock split ratio of 1-for-6	range from one-for-two (1-for-2) to one-for-ten (1-for-10)
Bonum Health Hub [Member]
Loss on inventory investments			$ 143,891
Trxade, Inc.[Member]
Equity method investment, ownership percentage				100%
SosRx LLC [Member]
Equity method investment, ownership percentage					51%
Exchange Health LLC [Member]
Equity method investment, ownership percentage					49%

SCHEDULE OF BASIC AND DILUTIVE

SCHEDULE OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Net loss	$ (3,909,868)	$ (5,315,883)
Numerator for basic and diluted EPS - income available to common stockholders	$ (3,472,099)	$ (5,315,883)
Denominator for basic and diluted EPS – weighted average shares	8,472,946	8,136,740
Basic and diluted loss per common share	$ (0.41)	$ (0.65)

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Feb. 28, 2022	Aug. 31, 2021
Product Information [Line Items]
Accumulated deficit	$ 19,719,536	$ 16,247,437
Working capital	54,000
Cash balance	1,133,633	3,122,578
Proceeds from Contributed Capital	1,500,000
Bad debt expense	246,683	(615,657)
Bad debt expense	(246,683)	615,657
Recovery of bad debt	247,861	247,861
Reserve for inventory obsolescence	0
Write down of inventory		376,348
Goodwill	$ 0	$ 0
Intangible assets			$ 792,000
Intangible asset useful life	15 years
Amortization of intangible assets	$ 44,100
Loss on impairment of goodwill	$ 792,000
Valuation allowance percentage	100%
Warrants issued	2,663,045			5,000
Warrants outstanding	2,689,969
Number of options outstanding	295,623
Cash, uninsured amount	$ 518,419
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customers [Member]
Product Information [Line Items]
Concentration risk, percentage	10%

SHORT-TERM DEBT AND RELATED P_2

SHORT-TERM DEBT AND RELATED PARTIES DEBT (Details Narrative) - USD ($)	1 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Dec. 31, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Related party debt			$ 166,667
Community Specialty Pharmacy, LLC [Member] | Related Party Promissory Note [Member] | Nikul Panchal [Member]
Short-Term Debt [Line Items]
Promissory note issued		$ 300,000
Interest rate		10%
Maturity date		Oct. 15, 2021
Notes converted	$ 75,000
Shares issued upon conversion	25,000
Share price per share	$ 3
Principal owed	$ 225,000
Loss on conversion of debt	$ 76,500
Related party debt			$ 0	$ 0

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)							1 Months Ended			12 Months Ended
	Dec. 13, 2022	Aug. 31, 2022	Dec. 10, 2021	Aug. 06, 2021	May 27, 2021	Apr. 15, 2021	Sep. 30, 2022	Jan. 31, 2022	Aug. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants exercised								14,584		14,584	5,000
Proceeds from warrant exercises								$ 875	$ 15,000	$ 875	$ 15,001
Warrants to purchase common stock, shares									5,000	2,663,045
Warrants exercise price									$ 3
Common stock, shares issued									5,000	9,393,708	8,166,457
Stock issued during period value issued for services										$ 254,106	$ 181,163
Shares available for grant, shares										1,407,276
Shares repurchased										0
Equity Distribution Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Deferring offering costs										$ 128,000
Shares of common stock sold										0
Maximum [Member] | Equity Distribution Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sale of common stock				$ 9,000,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, shares										920,000
Stock issued during period shares issued for services										292,667	37,905
Stock issued during period value issued for services										$ 2
Share based compensation, value							$ 37,000
Share based compensation, shares							31,896
Officers [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, shares		108,617
Shares price		$ 1.16
Board of Directors Chairman [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period shares issued for services										54,525
Stock issued during period value issued for services										$ 63,250
Stock issued to employees, restricted stock award shares	50,000
Board of Directors Chairman [Member] | Stock Repurchase Program [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock repurchase program description			There is no time frame for the repurchase program, and such program will remain in place until a maximum of 100,000 shares of the Company’s common stock has been repurchased or until such program is discontinued by the Board of Directors.		There is no time frame for the repurchase program, and such program will remain in place until a maximum of $1.0 million of the Company’s common stock has been repurchased or until such program is suspended or discontinued by the Board of Directors.
Board of Directors Chairman [Member] | Maximum [Member] | Stock Repurchase Program [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares repurchase value approved					$ 1,000,000
Shares repurchased			100,000
Board of Directors Chairman [Member] | 2021 Equity Compensation Awards [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Options to purchase shares of common stock						17,500
Options term						5 years
Exercise price per share						$ 4.76
Mr. Donald G. Fell, Dr. Pamela Tenaerts, and Mr. Michael L. Peterson [Member] | 2021 Equity Compensation Awards [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares of restricted stock						10,721
Shares of restricted stock, value						$ 55,000					165,000
Price per share						$ 5.13
Share based compensation											68,750
Mr. Peterson and Ms. Tenaerts [Member] | 2021 Equity Compensation Awards [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock redeemed or cancelled during period, shares					16,082
Michael L. Peterson and Dr. Pamela Tenaert [Member] | 2021 Equity Compensation Awards [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares of common stock vested					2,680
Charles L. Pope, and Christine L. Jennings [Member] | 2021 Equity Compensation Awards [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares of restricted stock					10,912
Shares of restricted stock, value					$ 41,250
Price per share					$ 3.78
Share based compensation											$ 64,167
Chief Executive Officer [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, shares										51,724
Chief Executive Officer [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Annual compensation										$ 360,000
Chief Executive Officer [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Annual compensation										$ 300,000
Chief Operating Officer [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, shares										8,620
Chief Operating Officer [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Annual compensation										$ 150,000
Chief Operating Officer [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Annual compensation										$ 140,000
Chief Financial Officer [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, shares										21,551
Chief Financial Officer [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Annual compensation										$ 225,000
Chief Financial Officer [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Annual compensation										$ 200,000

PREFUNDED AND PRIVATE PLACEME_2

PREFUNDED AND PRIVATE PLACEMENT WARRANTS (Details Narrative) - $ / shares	12 Months Ended
	Dec. 31, 2022	Aug. 31, 2021
Warrants to purchase price	2,663,045	5,000
Warrants price per share		$ 3
Pre Funded Warrants [Member]
Warrants to purchase price	601,740
Warrants price per share	$ 1.14999
Share exercise price per share	0.00001
Warrants exercise price per share	1.50
Warrants minimum exercise price	$ 0.232

SUMMARY OF ASSUMPTIONS USED TO

SUMMARY OF ASSUMPTIONS USED TO ESTIMATE FAIR VALUE OF WARRANTS GRANTED (Details)	Dec. 31, 2022	Dec. 31, 2021
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0	0
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	86	217
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	4.3	2.75
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, term	5 years	5 years

SCHEDULE OF OUTSTANDING AND EXE

SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Warrants
Number of outstanding shares, warrants outstanding beginning	44,535	44,535	82,751
Weighted average exercise price, outstanding beginning	$ 0.32	$ 0.32	$ 1.33
Contractual life in years warrants outstanding, beginning		11 months 12 days	2 years 8 months 23 days
Aggregate intrinsic value outstanding beginning	$ 208,078	$ 208,078	$ 352,951
Number of outstanding shares, warrants granted		2,663,045	5,000
Weighted average exercise price, warrants granted		$ 1.50	$ 3
Contractual life in years warrants outstanding, granted		4 years 9 months 7 days	1 year 5 months 23 days
Number of outstanding shares, warrants forfeited, expired, cancelled		(3,027)	(38,216)
Weighted average exercise price, warrants forfeited, expired, cancelled		$ 3.90	$ 2.51
Aggregate intrinsic value, warrants forfeited, expired, cancelled
Number of outstanding shares, warrants exercised	(14,584)	(14,584)	(5,000)
Weighted average exercise price, warrants exercised		$ 0.06	$ 3
Number of outstanding shares, warrants outstanding ending		2,689,969	44,535
Weighted average exercise price, outstanding ending		$ 1.50	$ 0.32
Contractual life in years warrants outstanding, ending		4 years 8 months 19 days
Aggregate intrinsic value outstanding ending		$ 6,731	$ 208,078
Number of outstanding shares, warrants exercisable ending		2,689,969
Contractual life in years warrants, warrants exercisable Ending		4 years 8 months 19 days
Aggregate intrinsic value warrants exercisable ending		$ 6,731

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Jan. 31, 2022	Aug. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Number of warrants granted			2,663,045	5,000
Warrants exercised	14,584		14,584	5,000
Proceeds from warrant exercises	$ 875	$ 15,000	$ 875	$ 15,001
Private Placement Warrants [Member]
Number of warrants granted			2,663,045
Warrants exercised			14,584
Warrants, expired and forfeited			3,027
Warrant [Member]
Number of warrants granted			2,663,045	5,000
Warrants exercised				5,000
Warrants, expired and forfeited				38,216
Warrants to purchase common stock			14,584	5,000
Proceeds from warrant exercises			$ 875	$ 15,000
Warrant valuation income/(expense)			$ 825,544	$ 0

SCHEDULE OF ESTIMATE FAIR VALUE

SCHEDULE OF ESTIMATE FAIR VALUE OF STOCK OPTIONS (Details)	12 Months Ended
	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected dividend yield	0%
Weighted-average risk-free interest rate	0.25%
Expected life of options	5 years
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average expected volatility minimum	102%
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average expected volatility maximum	207%

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - Stock Options [Member] - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options outstanding, beginning balance	410,964	425,817
Weighted average exercise price outstanding, beginning balance	$ 4.78	$ 4.44
Contractual life in years outstanding, beginning balance	4 years 8 months 1 day	5 years 3 months 29 days
Intrinsic value outstanding, beginning balance	$ 368,417	$ 597,332
Number of options exercisable, beginning balance	302,191	282,167
Weighted average exercise price exercisable, beginning balance	$ 4.88	$ 4.52
Contractual life in years exercisable, beginning balance	4 years 4 months 17 days	4 years 6 months 21 days
Intrinsic value exercisable, beginning balance	$ 257,186	$ 384,226
Number of options, granted		36,700
Weighted average exercise price, granted		$ 5.74
Contractual life in years, granted		4 years 2 months 8 days
Number of options, forfeited	(18,499)	(21,200)
Weighted average exercise price, forfeited	$ 5.82	$ 6.45
Contractual life in years, forfeited	4 years 10 months 28 days	4 years 1 month 9 days
Number of options, expired	(96,842)
Weighted average exercise price, expired	$ 5.74
Number of options, exercised		(30,353)
Weighted average exercise price, exercised		$ 0.06
Contractual life in years, expired	2 years 7 months 28 days
Number of options outstanding, beginning balance	295,623	410,964
Weighted average exercise price outstanding, ending balance	$ 4.40	$ 4.78
Contractual life in years outstanding, ending balance	3 years 11 months 1 day
Number of options exercisable, ending balance	257,506	302,191
Weighted average exercise price exercisable, ending balance	$ 4.42	$ 4.88
Contractual life in years exercisable, beginning balance	3 years 10 months 20 days

OPTIONS (Details Narrative)

OPTIONS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Proceeds from issuance of common stock	$ 130,918
Fair value of options granted		168,008	$ 557,308
Stock option expense	79,163	$ 187,273
Unrecognized compensation costs related to stock options	$ 29,729
Unrecognized compensation costs related to stock options, expected weighted average period	5 years
Share-Based Payment Arrangement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options to purchase common stock granted		36,700
Number of options, exercised	0	30,353
Options to purchase common stock forfeited	18,499	21,200
Options to purchase common stock expired	96,842	0
Options vesting period	4 years
Options grants in period, weighted average exercise price	$ 4.86
Option term	5 years
Proceeds from issuance of common stock		$ 1,821
Stock Option Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options to purchase common stock granted	2,333,333
Second Amended and Restated 2019 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock issued during period, shares	2,000,000
Share-based payment award, description	beginning in 2021 and ending in 2029 (each a “Date of Determination”), in each case subject to the approval and determination of the administrator of the plan (the Board of Directors or Compensation Committee) on or prior to the applicable Date of Determination, equal to the lesser of (A) ten percent (10%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares as determined by the administrator, provided that not more than 25 million shares of common stock may be issued pursuant to the exercise of incentive stock options pursuant to the plan. The administrator did not approve an increase in the number of shares covered under the plan as of April 1, 2021.

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Federal loss carryforwards	$ 4,030,755	$ 2,347,266
Less: valuation allowance	(4,030,755)	(2,347,266)
Deferred tax assets

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)		12 Months Ended
	Dec. 22, 2017	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Federal corporate income tax rate	35%	21%
Net operating loss carry forwards		$ 17,105,445

OTHER RECEIVABLES (Details Narr

OTHER RECEIVABLES (Details Narrative) - USD ($)		1 Months Ended	12 Months Ended
	Sep. 30, 2021	Jun. 30, 2022	Dec. 31, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Principal amount	$ 630,000
Attorney fees		$ 743,000	$ 630,000
Bad debt expenses	$ 630,000		248,000
Waxman [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Principal amount			$ 630,000

CONTINGENCIES (Details Narrativ

CONTINGENCIES (Details Narrative)			1 Months Ended			6 Months Ended	12 Months Ended
	May 14, 2021 USD ($)	Aug. 14, 2020 Integer	Feb. 28, 2022 USD ($)	Aug. 31, 2020 USD ($) Integer	Jul. 31, 2020 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Loss on inventory investment							$ 875,250	$ 1,226,426
Compensatory amount value	$ 425,000
Settlement payment amount			$ 225,000
Integra [Member] | Studebaker Defense Group, LLC [Member]
Down payment					$ 500,000
Number of nitrile gloves delivered | Integer		180,000
Loss contingency damages sought value					$ 500,000
Loss on inventory investment						$ 500,000
Integra [Member] | Sandwave Group Dsn Bhd [Member]
Down payment				$ 581,250
Number of nitrile gloves delivered | Integer				150,000
Loss contingency damages sought value				$ 581,250
Loss on inventory investment						$ 581,250
Integra [Member] | Crecom Burj Group Sdn Bhd [Member]
Loss contingency damages sought value				$ 581,250

SCHEDULE OF OPERATING LEASES (D

SCHEDULE OF OPERATING LEASES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Jan. 01, 2019
Property, Plant and Equipment [Line Items]
Recognition of Right to use assets	$ 1,051,815	$ 1,233,033
Lease 1 [Member]
Property, Plant and Equipment [Line Items]
Initial Lease Term	January 2021 to December 2021
Renewal Lease Term
New Initial Lease Term	January 2022 to December 2026
New Renewal Lease Term	January 2027 to December 2031
Recognition of Right to use assets		977,220	$ 534,140
Incremental Borrowing Rate	10%
Lease 2 [Member]
Property, Plant and Equipment [Line Items]
Initial Lease Term	November 2018 to November 2023
Renewal Lease Term	November 2023 to November 2028
New Initial Lease Term
New Renewal Lease Term
Recognition of Right to use assets			$ 313,301
Incremental Borrowing Rate	10%

SCHEDULE OF FUTURE MINIMUM PAYM

SCHEDULE OF FUTURE MINIMUM PAYMENTS FOR OPERATING LEASE LIABILITIES (Details)	Dec. 31, 2022 USD ($)
Leases [Abstract]
2023	$ 293,683
2024	302,494
2025	311,569
2026	320,916
Thereafter	105,531
Total minimum lease payments	1,334,193
Less: effect of discounting	(264,228)
Present value of future minimum lease payments	1,069,965
Less: current obligations under leases	195,475
Long-term lease obligations	$ 874,490

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Increase in right-of-use asset	$ 977,220
Lease payments	13,943
Operating lease amortization expense	181,218	$ 131,558
Payment for operating lease liabilities	$ 164,618	$ 131,153

SCHEDULE OF BUSINESS INTERESTS

SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Revenue	$ 11,448,265	$ 9,889,433
Gross Profit	5,451,216	4,745,965
Segment Assets	3,710,026	5,766,164
Segment Profit/Loss	(3,909,868)	(5,315,883)
Cost of Sales	5,997,049	5,143,468
Trxade, Inc.[Member]
Segment Reporting Information [Line Items]
Revenue	5,435,814	4,924,015
Gross Profit	5,433,641	4,921,084
Segment Assets	1,877,881	2,273,330
Segment Profit/Loss	1,924,355	1,977,938
Cost of Sales	2,173	2,931
Community Specialty Pharmacy, LLC [Member]
Segment Reporting Information [Line Items]
Revenue	1,175,474	1,652,841
Gross Profit	(90,678)	156,785
Segment Assets	(621,686)	(431,593)
Segment Profit/Loss	(469,778)	(128,563)
Cost of Sales	1,266,152	1,496,056
Integra Pharma LLC [Member]
Segment Reporting Information [Line Items]
Revenue	4,754,067	3,250,561
Gross Profit	25,343	(393,582)
Segment Assets	445,264	565,619
Segment Profit/Loss	(545,557)	(2,749,028)
Cost of Sales	4,728,724	3,644,143
Other Segments [Member]
Segment Reporting Information [Line Items]
Revenue	82,910	62,016
Gross Profit	82,910	61,678
Segment Assets	2,008,567	3,358,808
Segment Profit/Loss	(4,818,888)	(4,416,230)
Cost of Sales		$ 338

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)					1 Months Ended	12 Months Ended
	Mar. 01, 2023	Jan. 20, 2023	Jan. 06, 2023	Jan. 04, 2023	Jan. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Mar. 02, 2023
Subsequent Event [Line Items]
Prefunded warrants, exercised					14,584	14,584	5,000
Warrant [Member]
Subsequent Event [Line Items]
Prefunded warrants, exercised							5,000
Subsequent Event [Member] | Membership Interest Purchase Agreements [Member] | Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC [Member]
Subsequent Event [Line Items]
Sale of stock percentage		100%
Subsequent Event [Member] | Membership Interest Purchase Agreements [Member] | Alliance Pharma Solutions, LLC [Member]
Subsequent Event [Line Items]
Sale of stock consideration received		$ 125,000
Subsequent Event [Member] | Membership Interest Purchase Agreements [Member] | Community Specialty Pharmacy, LLC [Member]
Subsequent Event [Line Items]
Sale of stock consideration received		100,000
Subsequent Event [Member] | Master Service Agreement [Member]
Subsequent Event [Line Items]
Sale of stock consideration received		$ 266,000
Subsequent Event [Member] | Mr. Michael L. Peterson [Member]
Subsequent Event [Line Items]
Number of restricted stock issued				100,000
Options vesting fair value				$ 55,000
Subsequent Event [Member] | Mr. Michael L. Peterson [Member] | Services on the Board of Directors [Member]
Subsequent Event [Line Items]
Cash compensation				55,000
Subsequent Event [Member] | Mr. Michael L. Peterson [Member] | Services as the Chairman of the Audit Committee [Member]
Subsequent Event [Line Items]
Cash compensation				$ 20,000
Subsequent Event [Member] | Jeff Newell [Member]
Subsequent Event [Line Items]
Exercise price			$ 6.02
Share price			$ 0.00001
Subsequent Event [Member] | Jeff Newell [Member] | Warrant [Member]
Subsequent Event [Line Items]
Prefunded warrants, exercised			601,740
Subsequent Event [Member] | Jeff Newell [Member] | Restricted Stock [Member]
Subsequent Event [Line Items]
Restricted stock grant			79,062
Subsequent Event [Member] | White Lion Capital LLC [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	50,000
Subsequent Event [Member] | Agile Capital Funding L L C [Member] | Funding Agreement [Member]
Subsequent Event [Line Items]
Receivables, Net, Current								$ 787,500